Drugs / KJ103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06607016 | Oct 2024 → Dec 2025 overdue | anti-glomerular basement membrane disease | Shanghai Bao Pharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05274659 Comparator | May 2022 → Mar 2023 | — | Shanghai Bao Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KJ103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05274659 ↗ |
| Route | Intravenous | “after a single intravenous dose” NCT05274659 ↗ |